Food and Healthcare Press Releases Thursday August 29, 2019 08:23
RANCHO SANTA MARGARITA, California--29 Aug--PRNewswire/InfoQuest
  • Enhanced Portfolio Saves Time and Cost in Product Development Cycle

SweeGen, a nature-based sweetener company, announced the launch of its advanced stevia-based sugar reduction platform, BESTEVIA(R) TASTE SOLUTIONS. Product manufacturers will find the enhanced portfolio valuable in saving time and cost during their product development cycle. The platform is label friendly, nature-based, non-GMO, and cost competitive.

SweeGen previously built a distinctive non-GMO stevia platform and now enters a new business of product development for – amongst others - dairy, beverage, nutrition and confectionary with BESTEVIA(R) TASTE SOLUTIONS.

The company's portfolio and expanded services provide clients with more options for delivering a full-taste experience for sugar reduced food and beverages with a sweetness profile and mouthfeel of sugar-made products.

"Our clients are faced with challenges in formulating reduced sugar products without compromising taste. SweeGen has the product development expertise and creative building blocks to provide solutions. We are excited to introduce our BESTEVIA(R) TASTE SOLUTIONS which offers the sweet taste experience consumers prefer," said Shari Mahon, senior vice president of product development.

Mahon explains, "This platform enables my team and our clients to work together even closer. It is built on a strong stevia foundation, and is enhanced with our creative building blocks to provide a custom blended solution that delivers best tasting products."

For more information about BESTEVIA(R) TASTE SOLUTIONS, please visit www.sweegen.com.
About SweeGen

SweeGen, a nature-based sweetener company, develops, produces, and distributes non-GMO sweeteners to the food, flavor, beverage, nutrition, and pharmaceutical industries. SweeGen's robust product pipeline, intellectual property portfolio, dedicated manufacturing capacity, and R&D provide the foundation for innovation and delivery of high-quality sweeteners. For more information, please contact info@sweegen.com and visit SweeGen's website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Bestevia(R) Taste Solutions. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Sweegen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of Sweegen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Sweegen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Logo - https://mma.prnewswire.com/media/469549/Sweegen_Final_OT_Logo.pdf

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics